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The Alzheimer’s Imaging Consortium: Celebrating 20 years of creativity
and progressIn 1975, the National Institute on Aging was created, and
within a year, Alzheimer’s disease (AD) was declared the
fourth leading cause of death and the most prevalent demen-
tia disorder. However, as a new post doc in 1980, I soon
discovered the research value of imaging in AD, then largely
limited to structural CTand 133 Xe flow studies, was marked
by doubts of utility (limited to recognizing clinically silent
focal brain lesions), little public awareness (dementia vs
old timers disease-really!), and limited funding (see Fig. 1
which begins in 1985 as older funding records are not avail-
able). The past 30 years show that the NIH consistently
funded imaging research at well under 1% of the cost of
Medicare and Medicaid spending on AD.
By 1996, just 20 years later, the science of imaging the
dementias experienced global recognition in large measure
benefitting from technological advances. Zaven Khachatur-
ian’s AD centers were highly successful incubators of imag-
ing projects, the structural imaging prediction of future AD
from the MCI stage was replicated, longitudinal MRI and
FDG-PET studies were de rigueur, a preclinical diagnosis
was in sight, imaging and neuropathology were irrevocablyFig. 1. Medicare AD expenditures data sources: www.CMS.gov, https:
agingresearch.org/publications/view/59#.V8cG101TGM4. NIA AD imaging fund
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).linked, and combined imaging and CSF studies added
needed pathologic specificity to diagnosis. The future opti-
mistically hinted of contributions of PET-based molecular
diagnosis, the NIH-NIA dream leadership team of Richard
Hodes, Neil Buckholtz, Marcelle Morrison-Bogorad, and
Tony Phelps were conjuring up more big science, and imag-
ing outcomes entered clinical trials. The world had now
come to fear the coming AD epidemic and a rising tide of
financial opportunity lifted all boats.
In 1996 at the Fifth International Conference on Alz-
heimer’s Disease and Related Disorders in Osaka, Japan,
Philip Scheltens and I accepted the invitation of the Alz-
heimer’s Association’s conference program directors to
co-chair an imaging focused satellite interest group (later
to be called the Alzheimer’s Imaging Consortium or
AIC). The inaugural AIC was planned for the 1998 Interna-
tional Conference on Alzheimer’s Disease and Related Dis-
orders in Amsterdam. Philip and I worked with the
association to assemble a representative and interactive
program, and I was given the honor to deliver the first im-
aging plenary the day before at the “big” meeting, but all//www.alz.org/documents/national/report_ASG_alzplan.pdf, https://www.
ing data source: www.jalz.com.
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overflowed with participants in a too small and poorly air
conditioned conference room. Still, AIC #1 was a scientific
and social success. However, my 30-minute talk was cut
6 minutes, short by a chair whose timing erred. As a result,
I omitted the more challenging part of my presentation, an
example of how imaging could go beyond description and
prediction to mechanism identification. Well, in retrospect,
it probably was for the best that I did not deliver my
example. Evidence supporting AD as an energy deficient
disorder did not fare well over the years. But, the need to
reveal mechanisms of neurodegenerative disease, in hu-
mans during life, has endured and is today more needed
than ever. Such was the vision Philip and I intended to pro-
mote with the AIC. Philip Scheltens gave the next imaging
plenary 2 years later.
I think a vital part of our responsibility as scientists is to
review, comment, and celebrate the progress and accom-
plishments of our peers. In 1999, my colleagues, Heiko
Braak, Khalid Iqbal, Bill Jagust, Judes Poirier, Barry Reis-
berg, Jerzy Wegiel, and Thomas Wisniewski, and I elected
to donate 100% of the proceeds from our 1999 textbook,
“An Atlas of Alzheimer’s Disease” with Parthenon Publish-
ing to create two “neuroimaging prizes”. With the guidance
of Zaven Kachaturian, Richard Frank, and Peter Snyder, we
convinced the association to accept our donation and
deliver the first awards in 2006. Today these awards, re-
named the “de Leon Prize in Neuroimaging,” are managedand funded by the Alzheimer’s Association and are awarded
at the annual AIC meeting that accompanies the Alz-
heimer’s Association International Conference (AAIC). I
am confident we are doing the right thing, having honored
as of 2016, 22 of our most talented colleagues. I only
wish there were more resources.
Now just weeks after the 2016 Toronto AAIC meeting
which marked the 20th anniversary of the founding of
AIC, my AIC colleagues and I continue to salute those
who dare to think creatively, break barriers and take us all
to a new level of understanding of Alzheimer’s disease
through brain imaging.
My thanks and appreciation go to Dr. Peter Snyder,
Editor-in-Chief of “Alzheimer’s & Dementia: Diagnosis,
Assessment & Disease Monitoring” and Dr. Liana Aposto-
lova, guest editor for this special volume on neuroimaging
advances, for their excellent scientific contributions, our
friendship, and for offering me the chance to express my
appreciation. The next 20 years should be pretty inter-
esting.Mony J. de Leon
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